No Data
No Data
No Data
No Data
No Data
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Yahoo FinanceApr 17 04:35 ET
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development
GlobeNewswireApr 10 08:05 ET
Express News | MaxCyte Signs Strategic Platform License With Be Biopharma; Terms Not Disclosed
Moomoo 24/7Apr 2 08:09 ET
MaxCyte Signs Strategic Platform License With Be Biopharma to Support the Development of Engineer...
Stockhouse Apr 2 08:05 ET
MaxCyte(MXCT.US) Director Sells US$22,025 in Common Stock
$MaxCyte(MXCT.US)$ Director Johnston John Joseph sold 5,000 shares of Common Stock on Mar 26, 2024 at an average price of $4.405 for a total value of $22,025.Source: Announcement What is statement of
moomoo NewsMar 28 17:14 ET
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. Shares of Harrow, Inc. (NASDAQ:HROW) fell sharply in today's pre-market trading after p
BenzingaMar 20 05:32 ET
Captain moo : Yoooo mooer, Great to see you here in moomoo community! You are making an awesome progress with your first post. Have fun on your journey in making more friends here!
No Data
No Data
Vhetration69 : d
SLLS : Nice
Be a voice no echo : up
Trytosaveabit Be a voice no echo: Great phase 3 results!